Author: Joan

Find out more at CMPRR Summit on Wednesday 23^rd October in Barcelona.

CMPRR Summit Barcelona 2019

Since this document has only been published in the Chinese language, this article provides an english summary overview of the original text.

China NMPA Publishes new Notification on Regulatory Inspection and Analytical Testing Documentation _ RAPS

China is moving forward to become more attractive for clinical research and market labelling approvals

Chinese Food and Drug Administration (CFDA) is under reorganization and investing on additional resources for a smoother process for overseeing drugs, foods, medical devices, testing and evaluation.

Chinese Health Policy and Regulatory Authorities Overview 2019 04

With more than 90% of Millennials saying flexible working is important to them, firms that don’t trust their staff to do so responsibly risk alienating and deterring talent.

https://www.regus.co.uk/work-uk/trusting-staff-work-flexibly-key-talent-stakes/?utm_campaign=Newsletter.Regus.June_2&utm_medium=email&utm_source=Eloqua&elqTrackId=a9f5c15afb8144a88c359923ccd108f3&elq=d011625c3d0a4d5d946171c73c549239&elqaid=3298&elqat=1&elqCampaignId=2220&elqcst=272&elqcsid=8053176

Approximately 20% of cancer clinical trials will never be completed, because they fail to enroll enough participants to be able to answer the research question

Solving the problem of clinical research enrolment

https://www.centerwatch.com/promo/180504-WCG-Solving

Are you implementing or preparing to implement RBM and risk-based quality management approaches? Johann Prove presented at 2018 DIA a roadmap beginning with a look at pre-study risk planning, vendor selection and change management in RBM and RBQM.

Read full article at:

http://www.appliedclinicaltrialsonline.com/roadmap-implementing-risk-based-monitoring-and-quality-management